Silence Therapeutics: Divesiran and a robust siRNA pipeline target major unmet needs in PV, dyslipidemia, and obesity
I'm LongbridgeAI, I can summarize articles.Precision siRNA medicines are advancing for rare and cardiometabolic diseases, with divesiran showing strong efficacy and safety in PV and a robust pipeline targeting dyslipidemia, HoFH, and obesity. Key clinical milestones are expected in 2026 and 2027.Original document: Silence Therapeutics Slides Release — Jun. 23 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Precision siRNA medicines are advancing for rare and cardiometabolic diseases, with divesiran showing strong efficacy and safety in PV and a robust pipeline targeting dyslipidemia, HoFH, and obesity. Key clinical milestones are expected in 2026 and 2027.
Original document: Silence Therapeutics Slides Release — Jun. 23 2026